Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study

Journal Article · Thu Apr 15 04:00:00 EDT 2021 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2020.11.040· OSTI ID:23200835

Haslett, Kate ^[1]; Bayman, Neil ^[1]; Franks, Kevin ^[2]; Groom, Nicki ^[3]; Harden, Susan V. ^[4]; others, and

---

1. The Christie NHS Foundation Trust Wilmslow Road, Manchester (United Kingdom)
2. Leeds Cancer Centre, St. James’s University Hospital, Leeds Teaching Hospitals NHS Trust, Beckett Street, Leeds (United Kingdom)
3. Radiotherapy Trials Quality Assurance Team, Mount Vernon Hospital, Rickmansworth Road, Northwood (United Kingdom)
4. Department of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Hills Road, Cambridge (United Kingdom)

Not all patients with stage III non-small cell lung cancer (NSCLC) are suitable for concurrent chemoradiation therapy (CRT). Local failure rate is high for sequential concurrent CRT. As such, there is a rationale for treatment intensification.

• OSTI ID: 23200835
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 5 Vol. 109; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
FAILURES
FEASIBILITY STUDIES
LUNGS
NEOPLASMS
PATIENTS
RADIOTHERAPY